Brain Injury IP Protecting BR9001 and BR4044

The Intellectual Property (IP) portfolio protects the BR9001 and BR4044 drug products as Compositions based on patented, API-specific, Self-Micro-Emulsifying Drug Delivery (SMEDD) technology. The issued Methods of Use claims for AIS include use with and without Tissue Plasminogen Activator (TPa) drugs. Issued Methods of Use Claims cover therapeutic uses of BR9001 for indications beyond  AIS and TBI. The claims covering TBI uses of BR4044 include treatment of mild, moderate, and severe Concussion, non-hemorrhagic Closed Head Injury, and severe TBI with increased intracranial pressure.

US Patent
Intl Patents
Type of Claims
Descriptive Title
Scope
Issued
Pending
Oral Compositions of Matter
Self-Emulsifying Formulations
Use in AIS and TBI1,2
Issued
Pending
IV Compositions of Matter
IV Premix
Use in AIS and TBI
Issued
Pending
Methods of Treatment
Ischemic Stroke undergoing mechanical thrombectomy
Use in AIS and ACS3
Pending
Pending
Methods of Treatment
Head Injury
Use in TBI
1

AIS: Acute Ischemic Stroke

2

TBI: Traumatic Brain Injury

3

ACS: Acute Coronary Syndrome

Co-inventors, Dr. Michael Zeligs and Dr. Irwin Jacobs, have patented formulation technology, and formulation compositions enabling new therapeutic uses for the first-in-class API.  The formulation technology increases oral bioavailability and produces stable nano-emulsions for intravenous use of the API.

Contact Boulder BioScience, LLC, for information –  [email protected].

Skip to content